Effect of Qishenyiqi dropping pills combined with shakubaquvalsartan on cardiac function echocardiographic results and myocardial injury in patients with chronic heart failure combined with pulmonary hypertension
Zhao Yan-yan
Dong Ruo-sha
Jia Jian
Li Xiao-yan
Abstract：Objective To investigate the effects of Qishenyiqi dropping pills combined with angiotensin-receptor neprisin inhib-itors (ARNI) on cardiac function,echocardiographic results and myocardial injury in patients with chronic heart failure (CHF) and pul-monary arterial hypertension (PAH). Methods According to the random number table method,148 CHF patients with PAH admitted to the First Veterans Hospital of Hebei Province from August 2020 to August 2023 were divided into a control group (n=74,treated with conventional therapy+RNI therapy) and a study group (n=74,treated with Qishenyiqi dripping pills in addition to the regimen in the con-trol group). The world health organization functional class (WHO-FC),pulmonary arterial pressure,cardiac function and adverse re-actions were compared between the two groups. Meanwhile,the levels of serum copeptin,galactin-3 (Gal-3) and N-terminal pro-brain natriuretic peptide (NT-proBNP) were detected. Results After treatment,the WHO-FC Ⅰ-Ⅱ(51.35％ vs 20.27％) (31.08％ vs 16.22％) and WHO-FC Ⅲ-Ⅳ(48.65％ vs 79.73％) (68.92％ vs 83.78％) of the study group and control group were better than before treatment (all P<0.05),and the study group was better than the control group (all P<0.05). The left ventricular ejection fraction (48.43±5.87 vs 35.21±4.27) score (42.21±6.06 vs 36.04±4.43) score,stroke volume (52.38±5.43 vs 41.85±6.19) mL (47.91±6.07 vs 42.23±5.24) mL of the study group and the control group were all higher than those before treatment (all P<0.05). The pulmonary artery dia-stolic pressure (38.36±4.21 vs 56.43±6.08) mm Hg(1mm Hg≈0.133 kPa) (47.42±4.79 vs 57.04±5.11) mm Hg,pulmonary artery systolic pressure (18.29±4.86 vs 39.54±5.83) mm Hg (25.61±5.24 vs 40.03±6.12) mm Hg,and left ventricular end diastolic diameter (50.76)±3.96 vs 60.74±4.37) mm (56.43±4.21 vs 59.82±4.89) mm,left ventricular end systolic diameter (33.64±4.82 vs 46.57±5.36) mm (38.21±5.13 vs 45.29±4.27) mm,copeptin (18.52±5.41 vs 32.86±6.14) pmol·L-1 (23.28±5.84 vs 33.32±4.43) pmol·L-1,Gal-3 (3.37±1.12 vs 9.01±2.89) μg·L-1 (6.48±2.14 vs 9.24±3.02) μgg NT proBNP (630.46±111.23 vs 1353.58±211.64) pg·mL-1 (862.68±162.64 vs 1307.64±200.53) pg·mL-1 were all lower than those before treatment (all P<0.05),and the study group was better than the control group,the difference was statistically significant (all P<0.05). Conclusion The use of Qishenyiqi dropping pills and ARNI in the clinical treatment of patients with CHF and PAH can improve the pulmonary arterial hypertension,cardiac function,reduce pulmonary artery pressure,relieve heart function damage and do not increase drug-related adverse reactions.
Keywords：Qishenyiqi dropping pillsSacubitril valsartanChronic heart failurePulmonary arterial hypertensionCardiac function
Publication Date：2024-12-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 836-840 )